SS-31 vs MOTS-c: How the Mitochondrial Peptides Differ

SS-31 and MOTS-c are both described as mitochondrial peptides, but they come from different scientific ideas. SS-31, the research name for elamipretide, is a synthetic peptide designed to localise at the inner mitochondrial membrane. MOTS-c is a naturally encoded 16 amino acid signalling peptide made from a short open reading frame in mitochondrial DNA. The comparison is therefore less about deciding which one is "stronger" and more about understanding two different mechanisms backed by very different levels of evidence.

The shortest comparison

SS-31 has crossed the line from experimental mitochondrial biology into regulated medicine, although only for one rare disease. In September 2025 the FDA granted accelerated approval to Forzinity, containing elamipretide, to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg Regulator approved indication ¹. The approval is based on knee extensor muscle strength as an intermediate clinical endpoint and requires a confirmatory trial.

MOTS-c has no comparable human treatment record. FDA reviewers reported in July 2026 that they had not identified clinical studies evaluating administration of MOTS-c to humans, and that the clinical relevance of its cell and rodent findings remains unknown ². That does not make the biology uninteresting. It means claims about injected MOTS-c sit several steps earlier in the evidence chain.

Where each peptide comes from

SS-31 is synthetic. It is a short four residue peptide designed to enter cells and concentrate at the inner mitochondrial membrane. The FDA describes elamipretide as a mitochondrial cardiolipin binder that localises to that membrane and improves mitochondrial morphology and function Mechanistic Regulator approved indication ¹. Cardiolipin is a distinctive phospholipid that helps organise the membrane structures where oxidative phosphorylation takes place.

MOTS-c starts somewhere else. The original 2015 paper identified a short open reading frame within mitochondrial 12S rRNA that encodes a 16 amino acid peptide Mechanistic ³. In cell experiments and mice, MOTS-c altered folate and purine metabolism, increased AICAR and activated AMPK, a central cellular energy sensor In vitro Animal ³. Later work has explored its movement to the nucleus and other candidate signalling targets, but these remain mechanistic and preclinical findings rather than proof of a treatment effect in humans.

The biological distinction matters. SS-31 is aimed at membrane structure and cardiolipin related mitochondrial function. MOTS-c behaves more like a mitochondria derived signal involved in metabolic stress responses. Calling both "mitochondrial peptides" is accurate, but it can imply a similarity in action that is not really there.

What the human evidence says about SS-31

Elamipretide has a substantial clinical programme, and the results are mixed rather than uniformly positive. The largest trial in primary mitochondrial myopathy was MMPOWER-3, a phase 3 randomised double blind placebo controlled study in 218 participants. Treatment was given subcutaneously for 24 weeks. The trial missed both primary endpoints: the between group difference in six minute walk distance was minus 3.2 metres, with a 95% confidence interval from minus 18.7 to 12.3 metres, and the fatigue endpoint was also negative Human ⁴. The paper classified the result as Class I evidence that elamipretide did not improve those outcomes at 24 weeks.

Barth syndrome produced a different path. A small randomised double blind crossover trial enrolled 12 people with genetically confirmed Barth syndrome. During the controlled phase, neither the six minute walk test nor the symptom score primary endpoint showed superiority to placebo Human ⁵. Participants then entered an open label extension. At 36 weeks, eight participants remained, and the published study reported improvements from baseline in walking distance and symptom scores Human ⁵. Those later results were uncontrolled, so they cannot separate a drug effect from time, training, expectation or other changes.

The FDA's eventual approval used a different measure. Its 2025 label states that knee extensor muscle strength did not increase during the randomised part of the Barth study but did increase during the long extension period Regulator approved indication ¹. The agency accepted improvement in that measure as an intermediate clinical endpoint considered reasonably likely to predict benefit, which is why the indication was granted through accelerated approval rather than conventional approval based on confirmed clinical benefit.

This is an unusual evidence position. SS-31 has a real FDA approved indication, yet its largest mitochondrial myopathy trial was negative and the controlled phase of the small Barth trial also missed its main endpoints. Approval does not mean every mitochondrial claim about elamipretide is proven. It means the FDA judged the evidence sufficient for a specific rare disease, population and endpoint, with confirmatory work still required.

What the evidence says about MOTS-c

The strongest treatment findings for MOTS-c are still preclinical. In the 2015 discovery paper, administration to mice prevented diet induced obesity and improved insulin sensitivity in models of ageing and high fat feeding Animal ³. A 2021 study reported that administering MOTS-c improved physical performance in young, middle aged and old mice, while late life treatment improved physical capacity in very old mice Animal ⁶. The same paper also measured naturally occurring MOTS-c responses around exercise in people Human ⁶. Measuring a peptide that the body already makes is not the same experiment as administering it as a drug.

That distinction is central to this comparison. Human MOTS-c studies can show that the peptide exists in people, that its levels may change with exercise or disease, or that genetic variants are associated with metabolic traits. They cannot establish that giving synthetic MOTS-c causes weight loss, improves insulin sensitivity, increases fitness or slows ageing.

FDA reviewers reached the same boundary in their July 2026 compounding assessment. Their literature review did not identify clinical studies administering MOTS-c to human subjects. They found that the relevant pharmacology came from in vitro and in vivo rodent models, with important gaps in dose response information and uncertainty about molecular targets In vitro Animal ². FDA staff proposed that MOTS-c free base and MOTS-c acetate should not be added to the section 503A Bulks List on the evidence then available.

Why the mechanisms should not be blended together

The appeal of both compounds comes from the same broad problem: damaged or inefficient mitochondria are involved in many diseases and in some features of ageing. But a broad target such as "mitochondrial health" is not a single mechanism.

Elamipretide localises to the inner mitochondrial membrane and binds cardiolipin Mechanistic ¹. Barth syndrome is directly connected to cardiolipin biology because mutations in the TAFAZZIN gene disrupt cardiolipin remodelling. That gives SS-31 a disease specific mechanistic rationale that does not automatically carry over to healthy ageing or unrelated metabolic conditions.

MOTS-c is a signalling peptide encoded by mitochondrial DNA. The founding work linked it to folate metabolism, AICAR accumulation and AMPK activation Mechanistic In vitro Animal ³. Those pathways can influence glucose handling and energy use, which helps explain the metabolic interest. The missing step is demonstration that administering MOTS-c creates a useful, safe and reproducible effect in people.

Safety evidence is also very different

Elamipretide has human safety information from multiple clinical programmes. In MMPOWER-3, most adverse events were mild to moderate and the study reported that treatment was well tolerated Human ⁴. In the FDA approved Barth indication, the label says the most common adverse reactions were injection site reactions and also describes serious hypersensitivity reactions Regulator approved indication ¹. Those data belong to regulated elamipretide studied in defined clinical populations. They do not validate products sold outside the regulated medicine supply chain.

For MOTS-c, the FDA said in 2026 that potential human safety risks were unknown because of the lack of human administration data and the lack of information needed to assess immunogenic risk ². Animal tolerability cannot answer that question by itself.

What the regulatory difference means

In the United States, the difference is clear. Elamipretide is the active substance in an FDA approved medicine for a narrow Barth syndrome indication under accelerated approval Regulator approved indication ⁷. MOTS-c is not a component of an FDA approved drug, and FDA staff reviewing it for compounding in 2026 proposed against adding the free base or acetate form to the 503A Bulks List ². A compounding review is not a drug approval process, but it shows how different the two evidence records are.

The UK makes its own licensing decisions. A medicine needs a UK marketing authorisation before it can be sold or supplied as an authorised medicine in the UK ⁸. The MHRA has published a paediatric investigation plan record for elamipretide in Barth syndrome, but a paediatric investigation plan is part of development planning and is not itself a marketing authorisation ⁹. US approval should therefore not be read as automatic UK authorisation.

Which has the stronger evidence?

For an administered treatment in humans, SS-31 has the stronger evidence by a wide margin. It has several randomised clinical trials, a defined safety database and an FDA approved indication. That evidence is also a warning against broad claims: a major phase 3 trial was negative, the controlled Barth study missed its primary endpoints, and approval rests on a narrow rare disease setting with confirmatory work still required.

MOTS-c has the more speculative treatment story. Its biology is supported by cell, animal and observational human research, but the effects commonly promoted online from administering the peptide are not established in people. The two compounds should therefore sit in different evidence tiers even though both are discussed under the mitochondrial peptide label.

For readers who want the MOTS-c side in more depth, the BioRx guide to MOTS-c and the human evidence separates the animal work, human biomarker research and regulatory review.

Frequently asked questions

Is SS-31 the same thing as elamipretide?

Yes. SS-31 is a research name for the peptide developed as elamipretide. The FDA approved product uses elamipretide as its active substance for a specific Barth syndrome indication.

Is MOTS-c FDA approved?

No. FDA reviewers stated in 2026 that MOTS-c is not a component of an FDA approved drug. Their compounding assessment also reported that they had not identified clinical studies administering MOTS-c to humans ².

Does FDA approval mean SS-31 works for anti ageing or general mitochondrial health?

No. The FDA indication is specific to improving muscle strength in people with Barth syndrome who meet the label requirements. The approval does not establish benefit for healthy ageing, fitness, weight loss or general mitochondrial optimisation.

Has MOTS-c been shown to improve fitness in people?

No administered human study has established that effect. The best known performance findings come from mice, while human work has measured naturally occurring MOTS-c around exercise Animal Human ⁶.

Can SS-31 and MOTS-c be compared head to head?

There is no head to head clinical trial. Their mechanisms and development stages are different enough that a simple winner and loser comparison would be misleading. SS-31 has human treatment and regulatory data; MOTS-c remains primarily a mechanistic and preclinical research story.

More peptide questions

References

Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.

1. FDA prescribing information for Forzinity, September 2025
2. FDA Pharmacy Compounding Advisory Committee briefing on MOTS-c, July 2026
3. Lee C et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism.PubMed · DOI · View study in BioRx
4. Karaa A, Bertini E, Carelli V et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
5. Reid Thompson W, Hornby B, Manuel R et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
6. Reynolds JC et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications.PubMed · DOI · View study in BioRx
7. FDA grants accelerated approval to first treatment for Barth syndrome, 19 September 2025
8. MHRA, introducing new medicines in the NHS in the UK, marketing authorisation pathway
9. MHRA paediatric investigation plan record for elamipretide